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MaCardiovascular morbidity and mortality as a result of inhaled tobacco products continues to be a global healthcare crisis,
particularly in low- and middle-income nations lacking the infrastructure to develop and implement effective public
health policies limiting tobacco use. Following initiation of public awareness campaigns 50 years ago in the United
States, considerable success has been achieved in reducing the prevalence of cigarette smoking and exposure to
secondhand smoke. However, there has been a slowing of cessation rates in the United States during recent years,
possibly caused by high residual addiction or fatigue from cessation messaging. Furthermore, tobacco products have
continued to evolve faster than the scientiﬁc understanding of their biological effects. This review considers selected
updates on the genetics and epigenetics of smoking behavior and associated cardiovascular risk, mechanisms of
atherogenesis and thrombosis, clinical effects of smoking and beneﬁts of cessation, and potential impact of electronic
cigarettes on cardiovascular health. (J Am Coll Cardiol 2015;66:1378–91) © 2015 by the American College of Cardiology
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AB BR E V I A T I O N S
AND ACRONYM S
AAA = abdominal aortic
aneurysm
AF = atrial ﬁbrillation
BDNF = brain-derived
neurotrophic factor
CHD = coronary heart disease
CI = conﬁdence interval
CSE = cigarette smoke
exposure
CVD = cardiovascular disease
EC = electronic cigarette
EPC = endothelial progenitor
cell
MI = myocardial infarction
MMP = matrix
metalloproteinase
NO = nitric oxide
OR = odds ratio
PCI = percutaneous coronary
intervention
RR = relative risk
SC = smoking cessation
SHS = secondhand smoke
SNP = single-nucleotide
polymorphism
TF = tissue factor
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1379I nhaled tobacco products are highly engineered,pleasurable, and rapid delivery systems for nico-tine, a highly addictive substance, in addition
to numerous harmful toxicants and carcinogens
(1,2). When tobacco is burned, a complex chemical
mixture of more than 7,000 compounds is produced,
many of which are causally associated with prema-
ture deaths and diseases affecting nearly every organ
system in the body (2–4). Cigarette smoking is the
predominant form of tobacco exposure throughout
the world (5,6). Global estimates demonstrate a sig-
niﬁcant reduction in the prevalence of daily smoking
in both men and women between 1980 and 2012
(7,8). However, the total number of smokers world-
wide has increased during this period, from approx-
imately 721 million to 967 million, largely because
of population growth. The burden of disease
attributable to cigarette smoke exposure (CSE) and
secondhand smoke (SHS) is substantial, causing
6.3 million deaths annually and 6.3% of disability-
adjusted life-years (8). In Western Europe and high-
income North America, CSE and SHS are the leading
risk factors for morbidity and mortality, and globally
only high blood pressure is associated with a higher
burden of disease.
One-third of deaths from CSE are secondary to
cardiovascular disease (CVD) and 11.1% of these
deaths occur in people with exposed to SHS (9).
Extensive epidemiological research on SHS spanning
several decades supports a strong causal relationship
with a 25% to 30% increase in coronary heart disease
(CHD) (10–12). CSE has a nonlinear dose effect on CVD
and risk is increased at all levels of CSE, even among
persons smoking fewer than 5 cigarettes per day and
with exposure to SHS (13,14). Evidence also suggests
that the cardiovascular effects of CSE may have a low
threshold effect, with a marked increase in risk at
even low levels of exposure (Figure 1) (15). Thus, the
2014 report of the U.S. Surgeon General states “there
is no safe level of exposure to tobacco smoke” (3).
Although there have been signiﬁcant advances in
the understanding of the pathophysiology of tobacco-
related CVD, the pace of new research has slowed in
recent years. In addition, tobacco-related products
have continued to evolve more quickly than scientiﬁc
knowledge of their biological effects. There has been a
slowing of cessation rates in the United States during
recent years, possibly caused by high residual addic-
tion or fatigue from cessation messaging. Tobacco
control policies to protect persons from SHS in
public places are not universal and nearly one-third
of nonsmokers in the United States are passively
exposed to cigarette smoke. Tobacco products are
featured on the Internet and in media, and cigarettesremain remarkablyaffordable.Finally,despite
well-documented and devastating health con-
sequences, tobacco use continues to be under-
treated in the healthcare environment with
suboptimalimplementationofevidence-based
intervention (16).
This review focuses on selected tobacco-
related issues since the JACC review by
Ambrose and Barua in 2004 (17), including
mechanisms of CSE-related atherogenesis,
recent research on the genetics and epige-
netics of smoking behavior and the causal link
between tobacco use and CVD, the clinical
impacts of CSE/SHS and beneﬁts of legislation
to reduce SHS exposure, and consideration of
the potential cardiovascular effects of elec-
tronic cigarettes (ECs). The cardiovascular
effects of involuntary exposure to tobacco
smoke are not speciﬁcally addressed in this
paper, because this topic has been compre-
hensively reviewed in the report of the U.S.
Surgeon General (18). The authors’ purpose is
to reinvigorate commitment to advance the
scientiﬁc understanding of smoking behavior
and the cardiovascular effects of tobacco
products and newer forms of nicotine expo-
sure, to encourage advocacy efforts to more
broadly implement smoke-free policies, and
to make cessation counseling a clinical
imperative for every patient.
GENETICS AND EPIGENETICS OF
TOBACCO-RELATED CVDs
Genomic and epigenomic studies have provided
important insights into the risk for initiation of to-
bacco use, the intensity of smoking behavior, mech-
anisms of CSE-induced atherogenesis, and evidence
to support a causal association between CSE and CVD
risk (Table 1).
In the recent Tobacco and Genetic Consortium
meta-analysis of genome-wide association studies,
several common polymorphisms were found to be
robustly associated with smoking behavior (19). The
strongest evidence for association was a synonymous
single-nucleotide polymorphism (SNP) on chromo-
some 15q25 located in the nicotinic receptor gene
CHRNA (rs1051730). Among smokers, each additional
copy of the T allele of this SNP was associated with an
approximately 1 cigarette per day increase in the in-
tensity of smoking (p ¼ 2.8  10-72). Furthermore, a
nonsynonymous SNP (rs6265) on chromosome 11
in the brain-derived neurotrophic factor (BDNF)
gene (involved in nicotine-related dopamine reward
FIGURE 1 Dose-Response Relationship Between Cigarette Smoke Exposure and
Risk for Ischemic Heart Disease Events
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Data from studies of environmental tobacco smoke exposure and of active smoking
indicate that the relative risk of coronary heart disease events is signiﬁcantly
increased at even low levels of exposure. Adapted with permission from Law
et al. (15).
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1380circuits) was associated with increased odds of
smoking initiation (p ¼ 1.8  10-8). Each additional
copy of the C allele of the rs6265 SNP was associated
with an approximately 6% greater odds of regular
smoking (odds ratio [OR]: 1.06; 95% conﬁdence in-
terval [CI]: 1.04 to 1.08) (20).
In addition to providing important information
about genomic vulnerability to smoking behaviors,
the discovery of polymorphisms that are associated
with smoking intensity and the risk of initiating
tobacco smoking may provide a unique opportunity
to evaluate the causal effect of smoking on
the risk of CVD. Like other polymorphisms, the
smoking-associated rs1051730 and rs6265 SNPs are
allocated approximately randomly at the time ofconception in a process sometimes referred to as
mendelian randomization (21). Therefore, inheriting
an allele associated with greater smoking intensity is
analogous to being randomly allocated to more
intense smoking, whereas inheriting the other allele is
analogous to being randomly allocated to less intense
smoking. Comparing the risk of disease among
smokers with and without such an allele should,
therefore, provide a naturally randomized and un-
confounded estimate of the causal effect of more
intense (as compared with less intense) smoking on
the risk of disease in a manner analogous to a ran-
domized trial.
A recent mendelian randomization study con-
ducted among 55,568 persons from the Danish
general population found that the rs1051730 poly-
morphism in the nicotinic receptor gene was associ-
ated with both more intense smoking and with an
increased risk of all-cause mortality (22). These data
provide strong evidence that increasing smoking
intensity is causally related to an increased risk of
all-cause mortality. To date, however, the rs1051730
polymorphism has not been reported to be associated
with CVD events.
Another recent mendelian randomization reported
that a common SNP in the BDNF gene (rs492361, a SNP
in close linkage disequilibrium with rs6265) was
associated with a greater risk of ever having smoked
and a greater risk of both all-cause mortality and car-
diovascular mortality (23). In addition, the BDNF
rs6265 SNP was associated with a greater risk of CVD
among subjects studied in the CARDIoGRAMplusC4D
consortium studies (OR: 1.04; 95% CI: 1.02 to 1.06;
p ¼ 8.3  10-4) (24,25). Together, these data suggest
that exposure to tobacco smoking may be causally
associated with an increased risk of both all-cause
and cardiovascular mortality, and with an increased
risk of CVD events. These data must be interpreted
with caution, however, because both BDNF SNPs
studied are also associated with increased body mass
index (22,24). Because of the pleiotropic effect of
these SNPs, it is not possible using the available
evidence to determine how much of the association
between these BDNF SNPs and the risk of CVD and
totality mortality is mediated by smoking and how
much, if any, may be mediated by their effect on
body mass index.
CSE may also cause CVD through epigenetic ef-
fects. The best understood epigenetic effect is DNA
methylation, a covalent modiﬁcation that occurs pre-
dominantly at cytosines followed by guanines (CpG
dinucleotides) (26). CSE is one of the most powerful
environmental modiﬁers of DNA methylation (27),
and is strongly associated with a pattern of DNA
TABLE 1 Polymorphisms Associated With Smoking Behavior in
Genome-Wide Association Studies
Chromosome Nearby Genes SNP
Effect
Allele
Sample
Size
Effect
Size (SE) p Value
Smoking intensity: cigarettes per day
15q25 CHRNA3 rs1051730 A 73,853 1.02 (0.06) 2.7  10-73
10q23 LOC100188947
(noncoding
RNA)
rs1329650 G 73,853 0.37 (0.06) 5.7  10-10
rs1028936 A 72,956 0.45 (0.07) 1.9  10-9
8p11 CHRNB3-CHRNA6 rs6474412 T 84,956 0.29 (0.05) 1.4  10-8
rs13280604 A 76,670 0.31 (0.05) 1.3  10-8
9q13 EGLN2 rs3733829 G 73,853 0.33 (0.06) 1.0  10-8
near CYP2A6 rs4105144 C 83,317 0.39 (0.06) 2.2  10-12
CYP2A6 (*2
allele)
rs1801272 A 66,380 0.68 (0.18) 1.1  10-4*
CYP2B6 rs7260329 G 86,092 0.20 (0.04) 5.5  10-6*
Smoking initiation: odds of starting smoking
11p14 BDNF rs6265 C 143,023 1.06 (0.01) 1.8  10-8
Smoking cessation: odds of being a former smoker (former vs. current smokers)
9q34 near DBH rs3025343 G 64,924 1.12 (0.02) 3.6  10-8
Epigenetic effects: DNA hypomethylation among smokers
9p13 F2RL3 cg03636183 493 0.83 v.0.95 2.7  10-34
*p value less than the threshold for genome-wide signiﬁcance (p < 5  10-8).
SNP ¼ single-nucleotide polymorphism.
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1381methylation at distinct loci that can reliably distin-
guish between smokers and nonsmokers (18,26,28–30).
In recent epigenome-wide association studies, CSE was
strongly associated with hypomethylation of a CpG site
in the protease-activated receptor 4 gene (F2RL3).
The protease-activated receptors (PAR-1 and PAR-4) are
important mediators of thrombin-induced platelet
aggregation and are the targets of antiplatelet agents
that have been shown to reduce acute cardiovascular
events or are currently in development (31,32). CSE-
related hypomethylation of the F2RL3 gene may lead
to overexpression of the PAR-4 receptor, rendering
smokers more vulnerable to thrombin-induced platelet
aggregation, and thus providing a mechanistic link
between CSE and an increased risk of acute thrombotic
cardiovascular events. Indeed, F2RL3 hypomethylation
was found to be strongly associated with increased
cardiovascular and total mortality among smokers with
stable CHD (33).
Insights into the genetic and epigenetics of smok-
ing behavior and the cardiovascular effects of tobacco
exposure have provided an understanding of the
biology and behavioral basis for smoking-attributable
disease. Ongoing research is vital for the develop-
ment of therapies to prevent initiation of tobacco use
and for successful tobacco cessation.
MECHANISMS OF EFFECTS OF
TOBACCO PRODUCTS ON THE
CARDIOVASCULAR SYSTEM
PROPERTIES OF CIGARETTE SMOKE. The adverse
effects of CSE and SHS are mediated by the tar or by
the particulate phase and the gas phase, which both
contain signiﬁcant numbers of free radicals, resulting
in oxidative stress (Central Illustration) (2,34). Main-
stream smoke is inhaled by the smoker and is
comprised primarily of gaseous components (92%)
and some tar components (8%). Sidestream smoke is
unﬁltered and emitted from the burning end of a
cigarette. It contains a higher concentration of toxic
gaseous chemicals (polycyclic hydrocarbons and
volatile nitrosamines) than mainstream smoke, which
is inhaled by the active smoker (35). SHS is the com-
bination of the small amount of exhaled smoke from
the smoker (15%) and sidestream smoke (85%) (36).
INITIATION OF ATHEROGENESIS. Both direct CSE
and SHS cause vascular endothelial cell activation,
dysfunction, and damage. CSE affects the endothe-
lium through an increase in oxidative stress, with
effects on endothelial cell function and structure (1).
The scavenging activity of increased levels of super-
oxide and other reactive oxygen species produced byCSE, along with uncoupling of endothelial nitric
oxide (NO) synthase, leads to NO inactivation and
reduced availability of NO (37,38). CSE-induced NO
depletion causes a decrease in vascular responsive-
ness and a loss of antiadhesive properties of the
endothelium (1,36,39). Increases in macrophage and
platelet activity, along with impairment in the adhe-
siveness of monocyte-derived endothelial progenitor
cells (EPCs), may also contribute to endothelial cell
activation and dysfunction (1,40). CSE induces higher
expression and activity of matrix metalloproteinases
(MMPs) and lower expression of the MMP inhibitors,
thereby increasing the turnover of components of
the extracellular matrix (41,42). Deregulation of
MMP and MMP inhibitor activity may also impair
neovascularization in the diseased vessel wall. Nico-
tine also acts directly on cellular elements partici-
pating in plaque formation via stimulation of
nicotinic cholinergic receptors on the endothelium to
induce pathological angiogenic processes (43,44).
CSE is also associated with damage to the structural
integrity of the endothelium (1). CSE-induced oxida-
tive stress causes microtubule depolymerization
and proteasome-dependent degradation of a-tubulin.
The breakdown of cytoskeletal structures and inter-
mediate ﬁlaments result in collapse of the tubulin
system and contraction of vascular endothelial
cells (45,46). Furthermore, apoptosis and necrosis can
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Exposure to cigarette smoke and secondhand smoke (CSE/SHS) causes endothelial cell activation, dysfunction, injury, and death, leading to insudation of lipids and in-
ﬂammatory cells. The activation of leukocytes results in increased release of inﬂammatory cytokines, activation of NF-kB, and increased expression of adhesion molecules.
Increased inﬂammation, MMP activation, and reduced MMP inhibitors lead to the formation of rupture-prone plaques. Upon plaque rupture, CSE/SHS shifts the balance
toward a pro-thrombotic milieu with platelet activation, increased spontaneous platelet aggregation, increased platelet volume, increased platelet turnover, increased
plasmaﬁbrinogen, augmented clot strength, and reducedﬁbrinolytic capacity. EC¼ endothelial cell; eNOS¼ endothelial nitric oxide synthase; EPC¼endothelial progenitor
cell; ICAM¼ intercellular adhesion molecule; MMP ¼matrix metalloproteinase; NF ¼ nuclear factor; NO¼ nitric oxide; ROS¼ reactive oxygen species; TF ¼ tissue factor;
TFPI ¼ tissue factor pathway inhibitor; VCAM ¼ vascular cell adhesion molecule. Adapted with permission from Messner et al. (1) and Csordas et al. (165).
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1382occur from the impact of reactive oxygen species
and other components of cigarette smoke (38,47,48).
The necrotic death of endothelial cells leads to pro-
teolysis of extracellular matrix through the release of
lysosomal proteases (49).
EPCs play an important role in the response to
vascular injury and vascular neogenesis (50). The
number of circulating EPCs has been shown to be
inversely associated with Framingham cardiovascular
risk scores (51). In chronic smokers, the numbers ofcirculating EPCs are signiﬁcantly lowered as the
number of cigarettes consumed is increased, possibly
secondary to depletion from ongoing vascular injury,
and smoking cessation (SC) leads to a rapid recovery
of EPC levels (52). In healthy volunteers, active
smoking caused a rapid and signiﬁcant increase in the
number of circulating EPCs, suggestive of an imme-
diate response to CSE-related vascular injury (53).
CSE is associated with increases in inﬂam-
matory cells in the peripheral blood; increased
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1383leukocyte recruitment to the vascular endothelium
(1,54–56); augmented adhesiveness of leukocytes
and platelets to the vascular wall (57); and release
of pro-oxidant enzymes, such as myeloperoxidase
(Central Illustration) (58,59). The increase in reactive
oxygen species and oxidant-generating systems
induced by CSE leads to both systemic and local im-
mune system activation (60–62). Systemic inﬂamma-
tion is supported by increased expression of MMPs;
increased levels of proinﬂammatory cytokines, such
as tumor necrosis factor-a and interleukin-1b; and
elevated serum C-reactive protein among both active
and passive smokers (63–65). Activation of nuclear
factor-kB promotes surface expression of intercellular
adhesion molecule-1, vascular cell adhesion molecule-1,
E-selectin, and P-selectin by endothelial cells, as well
as by macrophages and platelets (66,67). Tumor ne-
crosis factor-a and interleukin-1b maintain sustained
activation of nuclear factor-kB, thereby perpetuating
the inﬂammatory response in smokers.
EFFECTS OF CSE ON COMPONENTS OF HEMOSTASIS
AND THROMBOSIS. CSE also plays an important role
in shifting the balance toward a prothrombotic cellular
and intravascular balance (Central Illustration) (68).
The turnover, structure, activation, and function of
platelets are strongly impacted by CSE, which causes
an increase in platelet reactivity and adhesiveness.
The number of newly formed reticulated platelets, a
measure of platelet turnover, is elevated in smokers
and is associated with an increased risk of thrombosis
(69). The serum mean platelet volume is also higher in
regular smokers compared with control subjects and
decreases signiﬁcantly at 3 months after SC (70).
CSE enhances platelet activation and spontaneous
platelet aggregation (71–75). Platelets isolated from
smokers exhibit a difference in the globular nature of
the platelet membrane visible by electron microscopy,
with surface pseudopodia being more pronounced in
smokers compared with healthy individuals (76).
These structural changes result in decreased platelet
membrane ﬂuidity and may cause an increase in
platelet activation and aggregation (77).
Plasma ﬁbrinogen levels of smokers are consis-
tently higher than levels in nonsmokers (78). Factor
XIII covalently cross-links and stabilizes the ﬁbrin
clot and levels of the A subunit of factor XIII are
signiﬁcantly increased in smokers (79). CSE is asso-
ciated with shortening of the time for ﬁbrin clot for-
mation, augmented clot strength, and an alteration in
ﬁbrin architecture (80). Fibrin clots in smokers have
thinner ﬁbers on electron microscopy, higher clot
turbidity, higher ﬁbrin ﬁber density, and more uni-
form ﬁber distribution.CSE is associated with an increase in tissue factor
(TF)-containing microparticles in the circulation
and in the number of tissue macrophages, the pre-
dominant source of TF in atherosclerotic plaques
(81,82). CSE reduces the expression of TF inhibitor by
the endothelium and increases circulating TF activity
(83,84). A strong association between the number of
cigarettes smoked per day and circulating TF activity
is indicative of a possible dose-response relationship.
TF pathway inhibitor-1 is a potent regulator of TF
factor VIIa-dependent activation of the TF pathway.
Smokers have a relative increase of the TF/TF
pathway inhibitor-1 ratio and an increase in throm-
botic potential (80).
CSE is associated with reduced ﬁbrinolytic capacity
and can adversely inﬂuence the ﬁbrinolytic balance
in the circulation (85). CSE is associated with
impaired coronary release of active tissue-type plas-
minogen activator and a dose-related increase in
plasma plasminogen activator inhibitor-1 antigen and
activity (86).
CLINICAL EFFECTS OF CSE
Clinical manifestations of CSE can be observed
throughout the spectrum of CVD. CSE increases
myocardial oxygen demand, resulting in shorter time
to the onset of angina (87). The risk of developing
CHD and myocardial infarction (MI) is several-fold
higher in cigarette smokers compared with non-
smokers (88,89). Compared with lifelong non-
smokers, both prior smoking and current smoking
increase the risk of developing heart failure by as
much as 33% to 93% (90,91). The risk does not seem to
be limited to smoking tobacco products, because
moist snuff has also been associated with a higher risk
of heart failure (92). Among patients with heart fail-
ure, continued smoking increases the risk of multiple
hospital admissions (OR: 1.82) (93).
CSE is the most important risk factor for the
development and severity of peripheral arterial dis-
ease. It increases the risk of peripheral arterial disease
by several-fold and is a more inﬂuential risk factor for
peripheral arterial disease than for CHD (94,95).
Abdominal aortic aneurysm (AAA) is the most com-
mon form of CSE-related aortic disease and the OR for
development of AAA is higher than that for CHD
(96,97). CSE has been associated with an increased
hazard for AAA incidence among women and men
who were current smokers with more than 20 pack-
years of exposure (hazard ratio: 10.97 and 6.55,
respectively) (98).
The association between stroke and CSE has
been demonstrated in multiple studies, in men and
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1384women of multiple ethnicities (99–101). Even expo-
sure to environmental tobacco smoke at home
during adulthood is associated with an increased
risk of stroke among never-smoking individuals
(100).
REVASCULARIZATION. CSE is associated with
adverse clinical outcomes following percutaneous
coronary intervention (PCI), particularly stent throm-
bosis (102–104). In the SYNTAX (SYNergy between
percutaneous coronary intervention with TAXus and
cardiac surgery) trial, patients who were smoking at
baseline and continued to smoke post-PCI had a
signiﬁcantly higher risk of stent thrombosis/graft oc-
clusion and MI compared with those who never
smoked (105,106). In the HORIZONS-AMI (Harmo-
nizing Outcomes with Revascularization and Stents in
Acute Myocardial Infarction) trial, smoking was an
independent predictor of reinfarction, and deﬁnite
stent thrombosis was responsible for 76.3% of rein-
farctions occurring within 30 days and 52.0% of rein-
farctions within 3 years (107). Current smoking was an
independent predictor of late or very late stent
thrombosis in the International Drug-Eluting Stent
Event Registry of Thrombosis, with events occurring
as late as 7.3 years post-PCI (108). Chronic smokingwas
also associated with a greater risk of deﬁnite stent
thrombosis in the PLATO (PLATelet inhibition and
patient Outcomes) study (109). A recent meta-analysis
of 30 studies of drug-eluting stents (4,276 cases of
deﬁnite stent thrombosis) conﬁrmed that smokingwas
an important risk factor for stent thrombosis (110). In
smokers, acute ST-segment elevation MI secondary to
stent thrombosis is associated with ﬁbrin-rich plaque
that is more amenable to thrombolytic/ﬁbrinolytic
therapy than plaque in nonsmokers (84,111,112).
Despite the risks associated with smoking following
PCI, approximately two-thirds of patients in a large
multicenter cohort of 2,765 patients with PCI remained
persistent smokers following intervention and had
worse disease-speciﬁc and overall health status
compared with never-smokers and quitters (113).
Following coronary artery bypass graft surgery,
CSE is associated with increased length of hospital
stay (114). Percutaneous and/or surgical reinterven-
tion following coronary artery bypass graft is more
common in smokers compared with nonsmokers
(115). Gene expression of MMP-2 and MMP-9 is
increased in female coronary artery bypass graft pa-
tients who are smokers or are exposed to SHS
compared with female nonsmokers, and is associated
with a decrease in saphenous vein graft patency (116).
Increased rates of late arterial occlusion following
peripheral artery surgical revascularization have beenreported in patients who continued smoking post-
operatively (117–119). CSE may also be associated with
an increased risk of restenosis after lower-limb endo-
vascular interventions (120). Both endovascular and
open repair of AAA are associated with poor survival
and increased morbidity in patients with pre-inter-
vention CSE (121,122). In octogenarians undergoing
urgent open repair of ruptured AAA, a history of CSE
was predictive of poor long-term outcomes (123).
ARRHYTHMIAS. CSE increases the incidence of both
atrial and ventricular arrhythmias, possibly because
of the proarrhythmic increase in sympathetic tone
from epinephrine and norepinephrine release asso-
ciated with nicotine exposure (124,125). The risk is
proportional to the quantity and duration of smoking.
CSE-induced endothelial dysfunction and inﬂamma-
tion are strongly associated with atrial ﬁbrillation
(AF) (126–129). Atrial ﬁbrosis, a proﬁbrillatory condi-
tion, has been demonstrated in human atrial tissue
slices from nonsmokers cultured in the presence of
nicotine base (130,131).
Several observational studies have reported on the
incidence of AF in smokers. In the Rotterdam study,
the incidence of AF in current and previous smokers
was higher than in nonsmokers (51% and 49% in-
creases, respectively), and was not affected by
adjustment for AF risk factors (132). The incidence of
AF was also higher in current and previous smokers
compared with nonsmokers in the Atherosclerosis
Risk in Communities study (133). Overall, smoking
doubled the incidence of AF. The risk was dose-
dependent and the highest smoking tertile was asso-
ciated with the highest risk of AF. Smoking also
increased the incidence of AF in the Manitoba Follow-
Up Study (134), whereas in the Framingham study,
smoking was associated with higher incidence of AF
in women, but not in men (135).
In a secondary analysis from MADIT-II (Multi-
center Automatic Deﬁbrillator Implantation Trial II),
the incidence of inappropriate shocks was 20% in
current smokers, 14% in ex-smokers, and 11% for
never-smokers (p ¼ 0.03 for the trend) (124,136). CSE
also increased the risk of appropriate implantable
cardioverter-deﬁbrillator shocks caused by fast ven-
tricular tachycardia (rate >180 beats/min) and ven-
tricular ﬁbrillation. In multivariate analysis, smoking
increased the risk of appropriate implantable
cardioverter-deﬁbrillator shock 2-fold compared with
nonsmokers.
Studies have demonstrated an increase in the risk
of sudden cardiac death in smokers. In the Bezaﬁ-
brate Infarction Prevention trial, the risk of sudden
cardiac death was signiﬁcantly increased (hazard
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(125). Ex-smokers had no increase in the risk of sud-
den cardiac death compared with nonsmokers. In the
Nurses’ Health Study, CSE signiﬁcantly associated
with an increased risk of sudden cardiac death (137).
This risk increased linearly with the quantity smoked
and the duration of smoking. SC reduced this risk
over time in a linear fashion.
SMOKING CESSATION AND
SMOKE-FREE LEGISLATION
In view of the strong relationship between CSE/SHS
and CVD, the elimination of this modiﬁable risk factor
is of particular importance. Overall, there is a robust
body of evidence supporting the beneﬁts of SC in
reducing cardiovascular events, overall mortality,
post-MI mortality, stroke, aortic disease, and pe-
ripheral vascular disease (138,139). Considering the
signiﬁcant beneﬁt of SC in reducing the risk of CVD,
SC programs are quite cost-effective and have lower
cost per net year of life gained compared with man-
agement of other risk factors (140,141).
The implementation of smoke-free ordinances has
been used as a “natural experiment” and proxy to
deﬁne the cardiovascular beneﬁts of reduced exposure
to SHS. Studies in several countries have shown that
smoke-free ordinances are associated with reductions
in the incidence and hospitalization rates for acute MI
(3). Although there is variation in the extent of smok-
ing restrictions, and differences in study methodol-
ogy, there is remarkable consistency in results
demonstrating reductions in CHD events associated
with smoke-free legislation, ranging from 6% to 47%.
A meta-analysis of 11 reports on smoking bans
found a 17% (incidence rate ratio [IRR]: 0.83; 95%
CI: 0.75 to 0.92) reduction in incidence of acute
MI, with incremental decreases of 26% per each year
of the ordinance implementation (142). In this meta-
analysis, the greatest beneﬁt was observed among
nonsmokers and younger individuals. A second meta-
analysis using 35 estimates of effect size from 17
studies found a pooled estimate of 0.9 (95% CI: 0.86 to
0.94) for the relative risk (RR) of acute coronary events
following the introduction of smoke-free legislation.
This study did not provide analysis by smoking status.
The effect was larger in studies with longer follow-up
after implementation (143). There was a signiﬁcant
degree of heterogeneity among studies included in
this meta-analysis, indicating the challenges of
measuring the effects of the smoking bans; however,
the results did not signiﬁcantly change when adjusted
for age, sex, population size, and location. A recent
meta-analysis of 45 studies examining 33 smoke-freelaws demonstrated that comprehensive smoking
bans were associated with lower rates of hospitaliza-
tion or death from coronary events (RR: 0.848; 95% CI:
0.816 to 0.881), cerebrovascular accidents (RR: 0.760;
95% CI: 0.682 to 0.846), and other heart disease (RR:
0.610; 95% CI: 0.440 to 0.847) (144). More compre-
hensive laws were associated with greater reductions
in hospitalizations (p ¼ 0.001), but the risk reduc-
tion for MI did not increase with longer follow-up
(p ¼ 0.537). The beneﬁt of more comprehensive legis-
lation was conﬁrmed in the most recent meta-analysis
of 31 studies providing estimates for 47 locations (145).
Following enactment of smoke-free laws between
1991 and 2010, there was a 12% reduction in hospitali-
zations for acute CHD events (RR: 0.88; 95% CI: 0.85
to 0.90). Reduction in risk was greatest in locations
with comprehensive legislation banning smoking in
indoor places and workplaces (14%) compared with
locations with only partial restrictions (8%).
CARDIOVASCULAR EFFECTS OF ECs
ECs have rapidly evolved and are marketed with of
claims of health beneﬁts compared with smoking
cigarettes including for reducing and quitting smok-
ing, for use when a person is forbidden to smoke
cigarettes, and for smoking without generating irri-
tating SHS. Despite claims, the primary health effects
of concern with EC use are lung disease and CVD. ECs
heat a nicotine solution to generate an aerosol that is
inhaled without combustion of tobacco and its toxic
combustion constituents (146,147). The devices
consist of a cartridge containing liquid (propylene
glycol, glycerin, nicotine, and ﬂavorings), a heating
element (atomizer), a battery, and a microchip
(Figure 2). The main EC aerosol constituents of
concern with respect to CVD are nicotine, carbonyls,
and particulates.
NICOTINE. Early studies of nicotine absorption from
older devices found that ECs delivered much lower
levels of plasma nicotine than conventional cigarettes
(148). More recent studies in more experienced users
using tank-type devices with larger batteries demon-
strate nicotine absorption similar to that of conven-
tional cigarettes (149). The main health concern for
nicotine in cigarette smokers is maintenance of
addiction. Tobacco combustion products cause most
of the adverse health effects of smoking, but some
health concerns are related to nicotine per se. Many of
these concerns are related to the ability of nicotine to
release catecholamines, including hemodynamic ef-
fects, adverse effects on lipids, and inducing endo-
thelial dysfunction and insulin resistance (2). Nicotine
in vitro and in animal models can inhibit apoptosis
FIGURE 2 Schematic Diagram of the Elements of an Electronic Cigarette and Pictures of 3 Generations of Electronic Cigarette Devices
Electronic cigarettes consist of a cartridge containing liquid (propylene glycol, glycerine, nicotine, and ﬂavorings), a heating element (atom-
izer), a battery, and a microchip. Cigalikes emulate the look of real cigarettes, although they may be slightly bigger and heavier. Second-
generation electronic cigarettes resemble a pen, are bigger and heavier, and have a larger battery capacity. These allow the user to customize
the e-liquid by varying ﬂavors and nicotine strengths. Third-generation devices include mechanical mods and variable voltage devices, using
larger batteries that can hold larger tanks of e-liquid. Courtesy of Dr. Gideon St. Helen, University of California-San Francisco.
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about the role of nicotine in promoting the accelera-
tion of atherosclerotic disease (42,43). Nicotine in ECs
has been shown to increase heart rate after overnight
abstinence (150). Short-term EC use was reported to
result in a small increase in diastolic blood pressure,
but unlike cigarette smoking, resulted in no diastolic
dysfunction and no reduction in coronary ﬂow veloc-
ity reserve, although the devices were low-nicotine
delivery devices (151,152).
The health effects of prolonged exposure to pure
nicotine, as experienced in the ongoing use of ECs,
are of concern. Evidence is available from studies of
prolonged exposure during nicotine-replacement
therapy in smokers who have quit smoking. No
adverse effects were reported when nicotine medi-
cation was administered for months to several years
(153). Patients with known CVD tolerate nicotine-replacement therapy well for periods up to 12 weeks
(154).
The health effects of smokeless tobacco have
been examined to assess potential long-term adverse
effects of nicotine without exposure to combustion
products. Smokeless tobacco users take in as much
nicotine as cigarette smokers, although not by
the pulmonary route (155). The most extensive and
rigorous epidemiological studies on smokeless
tobacco use comes from Scandinavia, where a large
percentage of men use snus, a smokeless tobacco
product that contains nicotine, but has relatively low
levels of carcinogens and other toxins. Most studies
report only a very small CVD risk in snus users
compared with tobacco smokers (156,157). A pooled
analysis of 8 prospective observational studies found
that current snus use was not associated with risk of
MI (hazard ratio: 1.04; 95% CI: 0.93 to 1.17). However,
J A C C V O L . 6 6 , N O . 1 2 , 2 0 1 5 Morris et al.
S E P T E M B E R 2 2 , 2 0 1 5 : 1 3 7 8 – 9 1 Cardiovascular Effects of Tobacco
1387the short-term case fatality rate was increased in snus
users (OR: 1.28; 95% CI: 0.99 to 1.68). A recent study
did ﬁnd that quitting smokeless tobacco use after a MI
substantially reduces mortality, suggesting a harmful
effect in people with CHD (158). Thus, although
adverse health effects of nicotine from ECs cannot be
ignored, they are likely to be much less than those of
CSE, which exposes the smoker to both nicotine and
to thousands of combustion-generated toxins.
CARBONYLS. Thermal degradation of propylene
glycol can generate propylene oxide, which is classi-
ﬁed by the International Agency for Research on
Cancer as a class 2B carcinogen. Heating glycerol can
result in formation of acrolein, an irritant and
oxidizing agent that is thought to contribute to the
adverse cardiovascular effects of CSE (159). Analyses
of emissions from cigarettes have found primarily
formaldehyde, acetaldehyde, and acrolein, along
with low levels of toluene, xylene, benzene, and
butadiene (160). Although these compounds are
potentially toxic, the levels in EC emissions are
many-fold lower than those found in CSE. The risk
of exposure to low levels of these compounds is
unknown. The intense heating of tank-model ECs
with large batteries results in generation of higher
amounts of formaldehyde and acetaldehyde, in some
cases similar to levels found in CSE (161). Formalde-
hyde is a carcinogen and irritant, but the cardiovas-
cular risks of prolonged inhalation of formaldehyde
at the levels found in EC aerosols are unknown.
PARTICULATES. ECs generate an aerosol consisting
of ﬁne and ultraﬁne particles in a gas phase. In a few
reports involving a limited number of devices and
liquids, the particle number and size distribution of
the mainstream aerosol generated by ECs was similar
to that of conventional tobacco cigarettes (162,163).
The number of particles in EC aerosol is inﬂuenced by
the liquid nicotine content and by pufﬁng time, and
higher levels of particles were generated by ECs
containing higher nicotine concentrations (162). Par-
ticles, such as those generated by ECs, can reach deep
into the lungs and potentially cross into the systemic
circulation. Particles present in CSE and ambient airpollution, which have a different composition than
EC particles, have been demonstrated to have ad-
verse cardiovascular and respiratory effects in human
and animal models (164). It is not known whether the
type of particles generated by ECs have the same
toxicity as particles present in ambient air or those
generated by conventional cigarettes, but this is an
important question for determining the long-term
safety of ECs.
CONCLUSIONS
Since the publication of the ﬁrst U.S. Surgeon
General’s Report in 1964, there have been signiﬁcant
advances in the mechanistic understanding of the
effects of CSE on the function of the cardiovascular
system, atherogenesis, vascular inﬂammation, and
thrombosis, although the pace of new scientiﬁc
research in this area has slowed in recent years (2).
There remains great potential for further insights into
individualized genetic and epigenetic components of
smoking behavior and CSE-related CVDs. Public
awareness campaigns and comprehensive smoke-free
legislation have achieved success in reducing the
initiation of smoking, increasing cessation, and
reducing passive exposure to SHS in public places in
the United States. However, rates of cessation have
slowed in recent years and there has been an overall
increase in the number of people who smoke world-
wide. To further reduce global morbidity and mor-
tality from tobacco use, it is essential to pursue
knowledge of the effects of CSE on the cardiovascular
system at a molecular level, to use genetic/epigenetic
and mechanistic insights to develop effective thera-
peutic and preventive modalities for treatment of
smoking behavior, and to continue development of
effective and targeted public health strategies to
discourage smoking initiation and encourage SC.
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